Project Grant R21AI193278
Award Date 8/3/26
Completion Date 7/31/28
Dollars Obligated $265K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Seattle, WA 98195, USA
Similar Awards
- The National Institute of Allergy and Infectious Diseases awarded $765,194 to the University of Washington on April 9, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to characterize the upper intestinal microbiota during human cholera and define the mechanisms by which host microbes impact cholera severity. The research compares the upper intestinal microbiota of people with mild to moderate cholera to those with severe disease, using emesis samples rather than...
- The National Institute of Allergy and Infectious Diseases awarded Wayne State University $452,600 on May 20, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to investigate Vibrio cholerae colonization and transmission factors in aquatic hosts. The research examines how pandemic O1 Vibrio cholerae establishes infection and spreads in zebrafish, a natural host model that recapitulates the complete infectious cycle with intact intestinal microbiota and immune...
- The National Institute of Allergy and Infectious Diseases awarded the University of Washington $296,414 on August 17, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to investigate effector-triggered inflammasome activation in rotavirus host defense and viral pathogenesis. The research addresses rotavirus as the primary cause of severe dehydrating diarrhea in children under age five, responsible for approximately two million hospitalizations and over 200,000 deaths...
- The National Institute of Allergy and Infectious Diseases awarded the University of Washington $824,264 on June 8, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to advance clinical readiness of PBVIVAC, a novel transgenic live attenuated sporozoite vaccine for Plasmodium vivax malaria. PBVIVAC combines P. berghei parasites engineered to express P. vivax circumsporozoite antigen, leveraging P. berghei's ease of laboratory propagation and natural attenuation in...
- The National Institute of Allergy and Infectious Diseases awarded the University of Virginia $242,250 on April 10, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to investigate microbial drivers of oral vaccine failure in undernourished populations. The research addresses environmental enteric dysfunction, a subclinical intestinal malabsorption syndrome linked to growth stunting and undernutrition. Oral rotavirus vaccination shows significantly reduced efficacy in...
- The National Institute of Allergy and Infectious Diseases awarded the University of Washington $3.414775 million in project grant funding on June 10, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to evaluate the immunogenicity and protective efficacy of a live attenuated Chlamydia trachomatis vaccine strain. The award funds rigorous preclinical evaluation of a mutant, live attenuated CT strain (CTGARD) in a nonhuman primate model that mimics human CT infection....
- The National Institute of Allergy and Infectious Diseases awarded the University of Washington $804,183 on July 16, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to design bifunctional chimeric proteins that redirect immune responses against antibiotic-resistant bacterial pathogens. The project applies deep learning-enabled protein design to create bacterial targeting chimeras (BacTACs) that simultaneously bind surface proteins on antibiotic-resistant bacteria...
- The National Institute of Allergy and Infectious Diseases awarded the University of Washington $233,250 on September 1, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855, Project Grant R21AI196802). The award funds research identifying genomic variation in CD101 and its association with functional characteristics of the innate immune response to bacterial vaginosis. The research examines how variants in CD101 may regulate mucosal inflammation and response to bacterial...
- The National Institute of Allergy and Infectious Diseases awarded the University of Washington $2,306,555 on February 1, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to conduct research on molecular determinants and functions of bacterial polysaccharide cellular localization. The research examines PSL and PEL exopolysaccharides in Pseudomonas aeruginosa biofilms, investigating how these polymers localize to cell surfaces and their roles in biofilm formation,...
- The National Institute of Allergy and Infectious Diseases awarded the University of Florida $750,263 on June 4, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to investigate how bacteriophage predation influences diarrheal disease severity and antimicrobial resistance emergence. The research uses cholera as a model system to validate findings in a new patient cohort and tests underlying theory across high-priority enteric pathogens including Shigella species and...